2023-506919-18-00已完成3 期
A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 873
- 试验地点
- 113
- 主要终点
- Change in the Clinical Dementia Rating – Sum of Boxes (CDR-SB) Score. From baseline (week 0) to week 104. Score on scale (0 to 18).
研究概览
简要总结
To confirm the superiority of oral semaglutide versus placebo on the change in cognition and function in subjects with MCI or mild dementia, both of the Alzheimer’s type
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Male or female, aged 55-85 years (both inclusive) at the time of signing informed consent
- •MCI or mild dementia of the Alzheimer’s type according to the NIA-AA 2018 criteria
- •CDR global score of 0.5 and CDR of 0.5 or more in at least one of the three instrumental activities of daily living categories (personal care, home & hobbies, community affairs) Or CDR global score of 1.0
- •Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) delayed memory index score of less than or equal to 85
- •Mini-Mental State Examination (MMSE) greater than or equal to 22
- •Amyloid positivity established with either amyloid positron emission tomography (PET) or cerebrospinal fluid (CSF) A beta 1-42 or CSF A beta 1-42/A beta 1-40
- •If receiving an approved Alzheimer's disease treatment (such as acetylcholinesterase inhibitors, memantine or aducanumab) the dose must have been stable for at least 3 months prior to screening and should not be changed during the trial unless medically necessary
排除标准
- •Brain magnetic resonance imaging (MRI) (or computerised tomography (CT)) scan suggestive of clinically significant structural central nervous system (CNS) disease confirmed by central read (e.g. cerebral large-vessel disease [large vessel (cortical) infarcts more than 10 mm in diameter], prior macro-haemorrhage [more than 1 cm3], cerebral vascular malformations, cortical hemosiderosis, intracranial aneurism(s), intracranial tumours, changes suggestive of normal pressure hydrocephalus)
- •Brain MRI (or CT) scan suggestive of significant small vessel pathology confirmed by central read and defined as more than 1 lacunar infarct and/or ARWMC more than 2,3 (WM more than 20 mm) in the deep white matter and periventricular regions
- •Brain MRI (or CT) scan suggestive of strategic infarcts defined as bilateral thalamic lacunar infarcts and singular paramedian thalamic infarcts confirmed by central read
- •Evidence of a relevant neurological disorder other than MCI or mild dementia of the Alzheimer’s type at screening, including but not limited to Parkinson’s disease, Lewy body disease, frontotemporal dementia of any type, Huntington’s disease, amyotrophic lateral sclerosis, multiple sclerosis, systemic lupus erythematosus, progressive supranuclear palsy, neurosyphilis, HIV, learning disability, intellectual disability, hypoxic cerebral damage, or significant head trauma with loss of consciousness that led to persistent cognitive deficits
- •Evidence of a clinically relevant or unstable psychiatric disorder, based on Diagnostic and Statistical Manual of Mental Disorders (DSM–5) criteria, including schizophrenia or other psychotic disorder, or bipolar disorder. A subject with a history of major depression who has not had an episode in the last 24 months before the day of screening and is considered in remission or who´s depression is controlled with treatment can be included in the trial per investigator’s judgement
研究组 & 干预措施
Rybelsus 7 mg tablets, Rybelsus 14 mg tablets, Rybelsus 3 mg tablets
Test
干预措施: Rybelsus 3 mg tablets (Drug)
Placebo (semaglutide) tablets
Placebo
干预措施: Placebo (semaglutide) tablets (Drug)
Rybelsus 7 mg tablets, Rybelsus 14 mg tablets, Rybelsus 3 mg tablets
Test
干预措施: Rybelsus 7 mg tablets (Drug)
Rybelsus 7 mg tablets, Rybelsus 14 mg tablets, Rybelsus 3 mg tablets
Test
干预措施: Rybelsus 14 mg tablets (Drug)
结局指标
主要结局
Change in the Clinical Dementia Rating – Sum of Boxes (CDR-SB) Score. From baseline (week 0) to week 104. Score on scale (0 to 18).
Change in the Clinical Dementia Rating – Sum of Boxes (CDR-SB) Score. From baseline (week 0) to week 104. Score on scale (0 to 18).
次要结局
- Change in the 24-item Alzheimer’s Disease Cooperative Study Activities of Daily Living Scale for MCI (ADCS-ADL-MCI) score. From baseline (week 0) to week 104. Score on scale (0 to 53).
- Time to progression to CDR global score ≥1.0 among patients with CDR global score = 0.5 at baseline. From baseline (week 0) up to week 156b.
研究者
EU Submission Hub
Scientific
Novo Nordisk A/S
研究点 (113)
Loading locations...
相似试验
招募中
3 期
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)2023-506918-45-00Novo Nordisk A/S798
招募中
3 期
A research study looking at the effect of semaglutide on the immune system and other biological processes in people with Alzheimer's disease2023-506825-13-00Novo Nordisk A/S13
招募中
3 期
An interventional, multi-center, randomized, double blinded, placebo controlled study to investigate semaglutide add-on treatment for metabolic control in antipsychotic-using patients (STABIL-NOR – study).2023-506109-20-00Helse Bergen HF140
终止
3 期
一项研究 Semaglutide 用于早期阿尔茨海默病患者的试验性研究（EVOKE plus）治疗阿尔茨海默病导致的轻度认知障碍（MCI）和轻度痴呆。CTR20212849丹麦诺和诺德公司 / 诺和诺德（中国）制药有限公司
尚未招募
不适用
Studying the Safety and Benefits of Oral Semaglutide for People with Diabetes and Obesity.CTRI/2025/04/085464Sri Ramachandra Institute Of Higher Education and Research45